ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Multimodal Investigation of Angiogenesis and Its Prevention by Small Compounds in a Zebrafish Cancer Model.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Heteronemin suppresses chemoresistant oral squamous cell carcinoma cells through ROS-mediated apoptosis and cuproptosis-associated mitochondrial stress.Apoptosis : an international journal on programmed cell death · 2026Article
- Multimodal Investigation of Angiogenesis and Its Prevention by Small Compounds in a Zebrafish Cancer Model.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Aberrant angiogenesis is a hallmark of many pathologies. In cancer, tumor growth and metastasis strongly depend on angiogenesis triggered by neoplastic cells. Antiangiogenic therapies are approved to treat different kinds of cancer. However, the success of these treatments is so far limited as some patients do not respond at all and others develop resistances. Thus, a deeper understanding of the mechanisms driving tumor angiogenesis and the variations in tumor vessels is crucial. Optical coherence tomography angiography (OCTA) is a fast volumetric imaging technique that provides detailed insights into tumor vascularization and perfusion of vessels in a label-free and non-invasive manner. An ultra-high resolution OCTA and confocal fluorescence imaging pipeline are developed to analyze tumor vascularization and blood perfusion in vivo, using a zebrafish cancer model. OCTA imaging operating at 800 nm is optimized to show slow blood flow allowing to compare the functionality of blood vessels in healthy and tumor-bearing zebrafish. Furthermore, effects of small compounds on tumor vascularization can be investigated with our setup. The key outcomes include a qualitative assessment of vascularization and blood vessel perfusion, along with a quantitative analysis of vessel structure, to evaluate how effective the drugs were at different concentrations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.